Takeda Pharmaceutical Co. has licensed the right to commercialize Teva Pharmaceutical Industries’ glatiramer acetate (active ingredient) formulation for the treatment of multiple sclerosis (MS), in Japan. Takeda will have commercialization rights in Japan and will submit a New Drug Application for registration in Japan. Financial details were not disclosed.   Teva’s glatiramer acetate for injection is indicated for the reduction of the frequency of relapses in relapsing-remitting MS, inclu...